Deals wrap: Genzyme bid hinges on new drug
Genzyme (GENZ.O), resisting a hostile bid from Sanofi-Aventis (SASY.PA), is open to a deal that links its value to the success of key drug Campath, the U.S. biotech’s chief executive was quoted as saying. But it was not up to Genzyme to suggest that to the French drugmaker, which has launched a $18.5 billion takeover offer for Genzyme, Chief Executive Henri Termeer was quoted as saying in French newspaper Le Figaro.
“This is one of the alternatives that could be explored. We are thinking about it with regard to the Campath molecule. This could be used by Sanofi or by other companies we talk to,” Termeer told the newspaper in an interview.
Global food companies are set to square up against emerging market buyers and private equity players to buy half of Yoplait, the world’s second-largest yogurt maker after French peer Danone (DANO.PA). General Mills (GIS.N), Nestle (NESN.VX) and Lactalis, Europe’s largest dairy group, all have sound strategic reasons to pursue the maker of Petits Filous yogurts and Yop drinking yogurt, valued at 1.5 billion euros ($2 billion) by its CEO Lucien Fa in a Reuters interview.
Spanish group Ferrovial has hired Goldman Sachs and HSBC to sell a 10 percent stake in BAA, Britain’s largest airport operator, and the sale will begin next week, people familiar with the matter said.
This week’s arrest of Don Ching Trang Chu, an employee at California-based expert-network firm Primary Global Research, is part of a “larger insider-trading case that is expected to continue unfolding between now and the end of the year,” reports the Wall Street Journal.